Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW: KSI-301 in NPDR
NCT05066230Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of tarcocimab tedromer, sponsored by Kodiak Sciences. Started Sep 2021; status: terminated.
02
Drugs
tarcocimab tedromer
Beyond the preview
Go deeper on NCT05066230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066230.